Abstract | INTRODUCTION: METHOD: Seventy-six patients with BMS (diagnosed according to the criteria in the literature and integrating the Diagnostic Interview Schedule-Revised for a complete psychiatric assessment), with no possible local or systemic causes and without concurrent major depression, were randomly assigned to receive amisulpride (50 mg/day), paroxetine (20 mg/day), or sertraline (50 mg/day). Efficacy assessments included a visual analogue scale (VAS) for pain intensity, the Hamilton Rating Scale for Depression (HAM-D), the Hamilton Rating Scale for Anxiety (HAM-A), and the Clinical Global Impressions scale (CGI). RESULTS: All 3 treatment regimens resulted in a significant improvement from baseline in burning mouth symptoms at week 8 as demonstrated by the quantitative (mean reduction in VAS, HAM-D, and HAM-A scores) and qualitative (percentage of responders) analyses. Amisulpride showed a shorter response latency than the SSRIs. No serious adverse events were reported, and the incidence of side effects did not differ among the 3 groups. None of the patients who received amisulpride withdrew from the trial, whereas withdrawal from the trial occurred within the first week of treatment in 11.5% of patients (N = 3) treated with paroxetine and in 21.7% of patients (N = 5) treated with sertraline. CONCLUSION: The data suggest that amisulpride and SSRIs may be effective treatments for BMS; they are equally effective and equally well tolerated in the short-term treatment of BMS. Amisulpride is associated with better compliance within the first week of treatment and with a shorter response latency in comparison with SSRIs. This finding may indicate that amisulpride is especially useful at the beginning of drug therapy of BMS. Double-blind, placebo-controlled trials are needed to further document the efficacy of amisulpride and SSRIs in the treatment of BMS.
|
Authors | Giuseppe Maina, Alberto Vitalucci, Sergio Gandolfo, Filippo Bogetto |
Journal | The Journal of clinical psychiatry
(J Clin Psychiatry)
Vol. 63
Issue 1
Pg. 38-43
(Jan 2002)
ISSN: 0160-6689 [Print] United States |
PMID | 11838624
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antipsychotic Agents
- Serotonin Uptake Inhibitors
- Paroxetine
- Sulpiride
- Amisulpride
- Sertraline
|
Topics |
- Amisulpride
- Antipsychotic Agents
(therapeutic use)
- Burning Mouth Syndrome
(drug therapy, psychology)
- Humans
- Male
- Middle Aged
- Paroxetine
(therapeutic use)
- Selective Serotonin Reuptake Inhibitors
(therapeutic use)
- Sertraline
(therapeutic use)
- Single-Blind Method
- Sulpiride
(analogs & derivatives, therapeutic use)
- Treatment Outcome
|